SKP2 Antibody

1. MiR-339 targets the 3'-untranslated region of Skp2 mRNA to depress the proliferation of lung cancer cells. PMID:29377618
2. Report that YAP is subject to non-proteolytic, K63-linked polyubiquitination by the SCF(SKP2) E3 ligase complex (SKP2), which is reversed by the deubiquitinase OTUD1. The non-proteolytic ubiquitination of YAP enhances its interaction with its nuclear binding partner TEAD, thereby inducing YAP's nuclear localization, transcriptional activity, and growth-promoting function. PMID:29891922
3. BTrCP-FBXW2-SKP2 axis forms an oncogene-tumour suppressor-oncogene cascade to control cancer cell growth with FBXW2 acting as a tumour suppressor by promoting SKP2 degradation. PMID:28090088
4. Result demonstrated that the overexpression of S-phase kinase-associated protein 2 (Skp2) was closely involved in the resistance of osteosarcoma cells to methotrexate and in the acquirement of EMT properties. PMID:29620168
5. The role of USP18 in breast cancer provides a novel insight into the clinical application of the USP18/AKT/Skp2 pathway. PMID:29749454
6. SKP2 promotes HCC progression and its nuclear functions of autophagy induction with CARM1 and AMPK, which may provide a potential target for HCC therapy. PMID:29991055
7. The results of the present study revealed that miR340 serves a tumor suppressor role by influencing the proliferation, apoptosis, migration and invasion of HCC cell lines, which may be explained by the downregulation of SKP2 by miR340. PMID:28944918
8. Our findings revealed that targeting Skp2 could be a promising therapeutic strategy for the treatment of Osteosarcoma PMID:28627672
9. Levels of p21 and p27 were decreased in TACO or pAKT overexpressing HCC due to SKP2 upregulation. PMID:27779207
10. Skp2 exhibited an oncogenic function in osteosarcoma cells. PMID:28771075
11. The results suggest that Skp2 repression is important for sustaining tetraploid G1 arrest after cytokinesis blockade and is required to prevent uncoupled DNA replication and nuclear division without cytokinesis. PMID:28648144
12. DCUN1D3 has a role in activating SCFSKP2 ubiquitin E3 ligase activity through cullin-1 neddylation and cell cycle progression in tumor cells with UV damage PMID:27542266
13. The expression of p-Skp2 was associated with p-mTOR in GC cell lines and tissues. Interestingly, the combination of p-Skp2 and p-mTOR was a better predictor of survival than either factor alone PMID:28446188
14. Atorvastatin strengthens Skp2 binding to FOXO1 or ICAM1, leading to ubiquitination and degradation. Skp2-dependent ubiquitination of major pathogenic molecules is the key mechanism for statin's protective effect on endothelial function in diabetes. PMID:28802579
15. we identified that rottlerin exhibited its anti-tumor potential partly through inactivation of Skp2 in breast cancer PMID:27582552
16. These findings indicated that SKP2 inhibition sensitized the prolactinoma cells to bromocriptine and helped promote apoptosis. PMID:27488872
17. Skp2 suppressed p53 and inhibited PIG3-induced apoptosis, while Skp2B attenuated the function of PIG3 by inhibiting PHB. PMID:27111245
18. Data suggest that targeting S-phase kinase associated protein 2 (SKP2) may serve as a potential radiosensitizer for developing effective therapeutic strategies against cervical cancer. PMID:27317767
19. Data indicate a positive correlation of Skp2 and MTH1 expression in melanoma cell lines and patient specimens. PMID:28947420
20. These results indicated that at least some oncogenic functions of BAG3 were mediated through posttranscriptional regulation of Skp2 via antagonizing suppressive action of miR-21-5p in ovarian cancer cells. PMID:28624440
21. High SKP2 expression is associated with Non-Small Cell Lung Cancer. PMID:28872922
22. Skp2-mediated degradation of Cygb was identified as the key mechanism for controlling its oscillating levels during the cell cycle. PMID:28948618
23. FOXM1 may play a central role in the skp2-cdk1 loop driving tumor progression. PMID:27684411
24. simvastatin also increased p21 and p27 expression in tumor sections by reducing Skp2 expression and inducing AMPK activation and STAT3 suppression in the same tumor tissues. PMID:28230855
25. Structural mimicry by a bacterial AnkB to human Skp2 hijacks the host ubiquitin-proteasome system. PMID:28111017
26. p27 and its cognate ubiquitin ligases, Skp2/KPC/Pirh2, are specifically involved in determining the clinical profiles of lung carcinomas. PMID:28601655
27. direct interactions of MAGE-A11 with Skp2 and cyclin A regulate the substrate-specificity of Skp2-mediated protein degradation. PMID:27720894
28. abnormal levels of Skp2 and p27(KIP1) have probably been involved in the pathogenesis of ADH and DCIS. Thus, Skp2 and p27(KIP1) may serve as important diagnosis markers PMID:28514182
29. High SKP2 expression is associated with lung cancer. PMID:28789966
30. our results revealed a novel mechanism in which EZH2 stability is regulated by SKP2 through the TRAF6-mediated and K63-linked ubiquitination, which contributes to elevated levels of H3K27me3 during prostate tumorigenesis and CRPC growth. PMID:27869166
31. Data demonstrate that AMPKa2 protein levels are reduced in bladder cancer and that this reduction is correlated with an increase in SKP2 expression with a concomitant reduction in p27 protein levels. PMID:27638620
32. SKP2 expression can inhibit radiation induced bystander effect of esophageal cancer cells. The mechanism may function, at least partly, through the regulation of Rad51 in the ability to repair DNA damage. PMID:28178195
33. AMPK deficiency results in nuclear CARM1 decrease mediated in part by SKP2, contributing to autophagy dysfunction in the aged heart. PMID:28315332
34. Higher expression of Skp2 correlates with lower expression of p27kip1 in gastric cancer tissues. PMID:27572672
35. The suppression of Skp2 reduced the enzyme activities of MMP-2. PMID:26874697
36. Data suggest that mternally expressed gene 3 (Meg3) long non-coding RNA and microRNA miR-3163 may coordinate suppression of translation of S-phase kinase associated protein 2 (Skp2) mRNA in non-small cell lung cancer (NSCLC) cells to inhibit cell growth. PMID:26482610
37. Data suggest that SIRT2 may induce Skp2 deacetylation and subsequent degradation to abolish the effects of Skp2 on p27 to affect NSCLC cell growth. PMID:26942878
38. High expression of SKP2 is associated with non-muscle invasive urothelial bladder carcinoma. PMID:26932430
39. HDACIs effects on Skp2 protein posttranslational modifications and/or on its removal PMID:26682002
40. miR-186 has a suppressive role in esophageal squamous cell carcinoma progression via SKP2-mediated pathway PMID:26568291
41. Patients with breast cancer have an increased SKP2 level. Interference in SKP2 gene expression can inhibit breast cancer cell growth. PMID:26345857
42. High expression of SKP2 is associated with Advanced Ovarian Cancer. PMID:26320455
43. Results demonstrate that curcumin exerts its antitumor activity through inhibition of glioma cell Skp2 pathway. PMID:26046466
44. TRUSS is a novel substrate of E3 ligase Skp2. PMID:26038816
45. Overexpression of LKB1 and Skp2 is found in hepatocellular carcinoma patients and predicts poor survival outcomes. PMID:25728766
46. The Skp2-mH2A1-CDK8 axis has a critical role in breast cancer development via dysregulation of the G2/M transition, polyploidy, cell growth dysregulation, and loss of tumor suppression. PMID:25818643
47. the Skp2mediated degradation of p27kip1 was important in the proliferation of tumor cells. The present study, therefore, provided a molecular reference for the treatment of liver cancer. PMID:25572801
48. Over-expression of Skp2 resulted in the increased cell growth and number of S phase cells in Skp2 transfected MCF-7 cells PMID:26429528
49. Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in prostate cancer cells via regulation of Skp2, p53, p21Cip1, and p27Kip1. PMID:25788262
50. Particularly for TNBC associated with Skp2/LRP6 overexpression. PMID:25358452

Show More

Hide All

HGNC: 10901

UNIGENE: Hs.23348

KEGG: hsa:6502

STRING: 9606.ENSP00000274255

OMIM: 601436